An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

Status Recruiting

Clinical Trial Summary

Definity (perflutren lipid microspheres, Lantheus Medical Imaging) is an ultrasound contrast indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. MVT-100 (the investigational pharmaceutical) is similar to Definity, with the exception of the removal of one lipid in the lipid blend and substitution of another lipid. This study is intended to evaluate the safety and efficacy of MVT-100 using a single ascending dose design in healthy volunteers. Patients are randomized to receive either MVT-100 or Definity and undergo echocardiograms after receiving either MVT-100 or Definity via bolus or IV infusion administration. The primary endpoints evaluated are safety and endocardial border delineation.

Clinical Trial Description

Ultrasound is one of the most common imaging examinations and has advantages of absence of ionizing radiation, portability and relatively low cost. Ultrasound contrast agents are used to improve the accuracy of ultrasound and Definity (perflutren) is the world's leading ultrasound contrast agent but perflutren has to be refrigerated and has a side effect of back pain. The investigators have developed a new, improved perflutren, MVT-100, with potential for room temperature storage. Ultrasound contrast agents are used to increase the backscatter (signal intensity of blood vessels and tissues to improve diagnostic accuracy) of ultrasound imaging. In the US ultrasound contrast agents are FDA approved for echocardiography to improve endomyocardial border definition. MVT-100 reflects the ultrasound to provide strong back-scattering. MVT-100 microbubbles resonate with ultrasound to provide strong harmonic signals. MVT-100 microbubbles will cavitate with higher levels of ultrasound and cavitation may be stable or inertial depending upon acoustic parameters and other factors. The study is a multi centre ascending dose comparison of Definity and MVT-100 for use in echocardiography and will be performed in a sample of healthy volunteers who are randomized to receive either Definity or MVT-100. This trial will assess safety and evaluate the following imaging metrics: - Determine the optimal dose of MVT-100 by comparing MVT-100 vs Definity in the change from baseline of quantitative left ventricular opacification - Evaluation of qualitative left ventricular opacification (LVO) - Evaluation of endocardial border delineation - Evaluation of endocardial border length - Evaluation of duration of useful contrast ;

Study Design

Related Conditions & MeSH terms

Heart Diseases

Clinical Trial Details

NCT number	NCT03882359
Study type	Interventional
Source	Microvascular Therapeutics, LLC
Contact
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	April 25, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04624412` - Different Intensities of Continuous Aerobic Exercises in Cardiac Rehab Phase 2	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT04561908` - Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access	N/A
Active, not recruiting	`NCT06190743` - Perception of Cardiovascular Risk
Completed	`NCT04580095` - Artificial Intelligence for Improved Echocardiography	N/A
Completed	`NCT04562636` - Evaluating a Messaging Campaign in the United States	N/A
Recruiting	`NCT03277365` - MyGeneRank: A Digital Platform for Next-Generation Genetic Studies	N/A
Active, not recruiting	`NCT05553106` - Evaluation of Cognitive Status, Kinesiophobia, Physical Activity Level, and Functional Performance in Coronary Intensive Care
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Enrolling by invitation	`NCT03314818` - Natural History of Carotid Plaque as Determined by 3D Ultrasound	N/A
Withdrawn	`NCT03289104` - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX	N/A
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02046902` - Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
Completed	`NCT01944254` - The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients	N/A
Completed	`NCT01909349` - Web-based Aftercare Intervention for Cardiac Patients	N/A
Recruiting	`NCT01457586` - Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery	Phase 4
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Recruiting	`NCT01541163` - Heart and Ischemic STrOke Relationship studY	N/A
Terminated	`NCT00968383` - Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.